Our data indicates that plasma visfatin levels are associated with HDL-C and markers of hyperandrogenism, but it is not associated with proinflammatory markers and insulin resistance in lean women with PCOS.

Introduction End-stage renal disease (ESRD) is a serious illness which has severe negative effects on patients' lives and quality of life. Aims To prospectively compare sexual functions between the women with ESRD and healthy women, and also to investigate risk factors that may cause sexual dysfunction in women with ESRD. Methods The study included 249 women, and the women were divided into two groups: 131 women with ESRD and 118 healthy women as a control group. After obtaining demographic characteristics, sexual function was evaluated with a detailed 19-item questionnaire (The Female Sexual Function Index [FSFI]) assessing sexual desire, arousal, lubrication, orgasm, satisfaction, and pain during sexual intercourse. Main Outcome Measures The FSFI scores were compared between the two groups, and risk factors that might cause sexual dysfunction were also investigated in the women with ESRD. Results The mean FSFI total score was significantly lower in the ESRD group (15.9 ± 10.4) than in the control group (22.2 ± 6.8) (P =0.001). The women with ESRD had also significantly lower mean score of sexual desire (P = 0.006), arousal (P = 0.001), lubrication (P =0.001), orgasm (P =0.001), satisfaction (P =0.001), and pain (P =0.024) than in the control group. To investigate risk factors for sexual dysfunction in the ESRD group, the women having hemodialysis, compared to the women having peritoneal dialysis, had a 5.23 times greater risk of developing sexual dysfunction (P = 0.001). Conclusions This study shows that women with ESRD have higher risk of sexual dysfunction than healthy women. Thus, women with ESRD should be consulted for sexual dysfunction to improve the quality of life.

Introduction Sexual dysfunction is more prevalent in postmenopausal women. Aims To prospectively evaluate and compare the effects of hormone therapy (HT) regimens, oral and vaginal estradiol, estradiol+drospirenone and tibolone, on sexual function in healthy postmenopausal women. Methods The study included 169 consecutive healthy postmenopausal women, and the women were divided into two groups: 111 women received HT, and 58 women received no treatment and served as a control group. As an HT, 23 women with surgically induced menopause received oral 17-β estradiol. The rest of the women with natural menopause were prospectively randomized: 22 received oral 17-β estradiol+drospirenone daily, 42 received oral tibolone, and 24 received vaginal 17-β estradiol. Sexual function was evaluated with a detailed 19-item questionnaire, the female sexual function index, including sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Main Outcome Measures The differences in sexual function were compared before and 6 months after the treatment in all women. Results Total sexual function score increased from 19.81 ± 7.15 to 22.9 ± 6.44 in the HT group and decreased from 21.6 ± 8.69 to 17.6 ± 5.7 in the control group, revealing a significant difference from baseline to post-treatment between the two groups (P =0.000). The highest improvement in total score and arousal was achieved with the oral 17-β estradiol (P =0.000 and P =0.000, respectively). The highest improvement in lubrication was achieved with the oral and vaginal 17-β estradiol groups (P =0.000). The highest improvement in orgasm was achieved with the tibolone group (P =0.000). The highest improvement in pain was achieved with the oral and vaginal 17-β estradiol groups (P =0.000). Conclusions HT provided significant improvement in sexual function compared to women receiving no treatment, and therefore, HT regimens should be suggested for improvement in sexual functioning of postmenopausal women.

BackgroundGestational diabetes mellitus (GDM), which has been identified for the first time during pregnancy and is defined as glucose intolerance of varying degrees, is one of the prediabetes states that are at risk for developing type 2 diabetes. MicroRNAs (miRNAs) are associated with pregnancy complications and are even necessary for the regulation of pancreatic development and glucose-induced insulin secretion. This study aims to investigate miRNAs expressed in maternal plasma to detect the availability as a biomarker in the diagnosis of GDM.MethodsIn this study, 30 pregnant women with GDM diagnosed according to GDM American Diabetes Association criteria and 30 healthy pregnant women were included and miRNA expression levels were investigated. Circulating 39 miRNAs were analyzed by qRT-PCR using 96.96 Dynamic Array IFCs.ResultsThe findings showed that the expression level of miR-7-5p significantly upregulated when compared with healthy pregnant women with gestational diabetes (fold change:2.3, p<0.05).ConclusionsThere is controversy about what is the most appropriate test for GDM screening. Therefore, supported by further studies, miR-7-5p can be used for the diagnosis of GDM.

Our findings show that sexual functions may be impaired after surgery for SUI. Burch colposuspension may deteriorate sexual functions much more than vaginal sling surgery in women. Therefore, women who will need surgery for SUI should be informed of the risk of deterioration of sexual function after surgery.